[1]陈 璐.温阳健脾汤治疗慢性萎缩性胃炎癌前病变的疗效及安全性[J].医学信息,2021,34(01):167-169.[doi:10.3969/j.issn.1006-1959.2021.01.046]
　CHEN Lu.Efficacy and Safety of Wenyang Jianpi Soup in the Treatment of CAG-PLGC[J].Medical Information,2021,34(01):167-169.[doi:10.3969/j.issn.1006-1959.2021.01.046]
点击复制

温阳健脾汤治疗慢性萎缩性胃炎癌前病变的疗效及安全性()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年01期
页码:
167-169
栏目:
中医中药
出版日期:
2021-01-01

文章信息/Info

Title:
Efficacy and Safety of Wenyang Jianpi Soup in the Treatment of CAG-PLGC
文章编号:
1006-1959（2021）01-0167-03
作者:
陈 璐
（大连医科大学附属第二医院中医科，辽宁 大连 116021）
Author(s):
CHEN Lu
(TCM Department,the Second Affiliated Hospital of Dalian Medical University,Dalian 116021,Liaoning,China)
关键词:
温阳健脾汤; 胃癌前病变; 慢性萎缩性胃炎
Keywords:
Wenyang Jianpi soup; Gastric precancerous lesions; Chronic atrophic gastritis
分类号:
R573.3+2
DOI:
10.3969/j.issn.1006-1959.2021.01.046
文献标志码:
A
摘要:
目的 通过观察温阳健脾汤对慢性萎缩性胃炎癌前病变患者的病理疗效及用药安全性，以期为中医药临床诊治此类疾病提供依据。方法 收集2018年1月~2019年3月在我院进行中医汤药治疗的慢性萎缩性胃炎癌前病变患者48例，给予温阳健脾汤治疗12周，比较治疗前后中医证候总积分、病理组织学积分、中医证候疗效、病理疗效进行评价，并对用药安全性进行评估。结果 治疗后中医证候总积分、病理各组积分均较治疗前下降，差异有统计学意义（P＜0.05）。中医证候疗效总有效率为83.33%，病理疗效总有效率为89.58%，且治疗后均未发生严重药物不良反应。结论 温阳健脾汤对胃癌前病变患者的临床症状及病理组织学改变均有良好的改善作用，效果显著，且用药安全可靠。
Abstract:
Objective To observe the pathological efficacy and drug safety of Wenyang Jianpi soup on patients with precancerous lesions of chronic atrophic gastritis, in order to provide a basis for the clinical diagnosis and treatment of such diseases in traditional Chinese medicine.Methods A collection of 48 patients with precancerous lesions of chronic atrophic gastritis who were treated with TCM decoctions in our hospital from January 2018 to March 2019 were treated with Wenyang Jianpi soup for 12 weeks. The total scores of TCM syndromes and histopathology were compared before and after treatment. Score, evaluate the curative effect of TCM syndrome, pathological curative effect, and evaluate the safety of medication. Results After treatment, the total score of TCM syndromes and the scores of each pathology group decreased compared with that before treatment,the difference was statistically significant(P＜0.05). The total effective rate of TCM syndrome curative effect was 83.33%, the total effective rate of pathological curative effect was 89.58%, and no serious adverse drug reactions occurred after treatment.Conclusion Wenyang Jianpi soup has a good effect on improving the clinical symptoms and histopathological changes of patients with gastric precancerous lesions, the effect is significant, and the medication is safe and reliable.

参考文献/References:

[1]Bray F,Ferlay J,Soerjomataram I,et al.Global Cancer Statistics 2018:GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 countries[J].CA,2018,68(6):394-424. [2]陈灏珠,林果为.实用内科学[M].13版.北京:人民卫生出版社,2010:2056. [3]Du Y,Bai Y,Xie P,et al.Chronic gastritis in China:a national multi-center survey[J].BMC Gastroenterology,2014,14(1):21. [4]黄远程,潘静琳,黄超原,等.慢性萎缩性胃炎癌前病变证型、证素演变规律文献研究[J].中医杂志,2019,60(20):1778-1783. [5]中华医学会消化病学分会.中国慢性胃炎共识意见(2017年,上海)[J].胃肠病学,2017,22(11):670-687. [6]中华中医学会脾胃病分会.慢性胃炎中医诊疗专家共识意见(2017)[J].中华中医药杂志,2017,32(7):3060-3064. [7]CFDA.中药新药临床研究指导原则(试行)[M].北京:中国中医药科技出版社,2002:126-127. [8]魏海瑛,王志飞.健脾通络解毒方加减辨治慢性萎缩性胃炎癌前病变临床观察[J].现代中西医结合杂志,2019,28(12):1296-1303. [9]崔一鸣,周斌.慢性萎缩性胃炎寒湿入络病机探讨[J].中华中医药杂志,2012,27(5):1327-1329. [10]李达,李在林.党参多糖作为免疫佐剂的研究综述[J].中国医药指南,2013,11(28):56-57. [11]孙文平,李发胜,陈晨,等.白术多糖对小鼠免疫功能调节的研究[J].中国微生态学杂志,2011,23(10):881-886. [12]陈晨,刘倩,高华.活血化瘀药药理作用研究进展[J].中国药事,2011,25(6):603-605. [13]廉艳红,赵兵,周斌.温阳健脾汤治疗脾胃虚弱型慢性萎缩性胃炎的临床疗效观察[J].中华中医药杂志,2017,32(6):2814-2817.

相似文献/References:

[1]铉 力,王晓红,胡 兵.胡兵教授治疗胃癌前病变的经验举隅[J].医学信息,2020,33(03):158.[doi:10.3969/j.issn.1006-1959.2020.03.052]
　XUAN Li,WANG Xiao-hong,HU Bing.Professor Hu Bing’s Experience in Treating Gastric Precancerous Lesion[J].Medical Information,2020,33(01):158.[doi:10.3969/j.issn.1006-1959.2020.03.052]
[2]石以石则,李婷婷,陈 威,等.化痰祛瘀法联合西药治疗胃癌前病变的Meta分析[J].医学信息,2022,35(07):99.[doi:10.3969/j.issn.1006-1959.2022.07.024]
　SHI Yi-shi-ze,LI Ting-ting,CHEN Wei,et al.Meta-analysis of Dissipating Phlegm and Removing Blood Stasis Combined with Western Medicine in the Treatment of Gastric Precancerous Lesions[J].Medical Information,2022,35(01):99.[doi:10.3969/j.issn.1006-1959.2022.07.024]

更新日期/Last Update: 1900-01-01